<h4>Background</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the treatment of type 2 diabetes and, more recently, for weight management among individuals without diabetes.<h4>Aim</h4>This review synthesizes the current evidence on the mechanisms by which GLP-1 RAs affect BP, their clinical effects across populations, and the implications for patient care. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.